- Home
- PRFX vs AEON Comparison
PRFX vs AEON Comparison
Compare PRFX & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- AEON
- Stock Information
- Founded
- PRFX 2007
- AEON N/A
- Country
- PRFX Israel
- AEON United States
- Employees
- PRFX N/A
- AEON N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- PRFX Health Care
- AEON Health Care
- Exchange
- PRFX Nasdaq
- AEON Nasdaq
- Market Cap
- PRFX 3.8M
- AEON 4.2M
- IPO Year
- PRFX 2020
- AEON N/A
- Fundamental
- Price
- PRFX $2.32
- AEON $0.46
- Analyst Decision
- PRFX Hold
- AEON Strong Buy
- Analyst Count
- PRFX 1
- AEON 1
- Target Price
- PRFX N/A
- AEON $360.00
- AVG Volume (30 Days)
- PRFX 3.8M
- AEON 465.0K
- Earning Date
- PRFX 05-14-2025
- AEON 05-13-2025
- Dividend Yield
- PRFX N/A
- AEON N/A
- EPS Growth
- PRFX N/A
- AEON N/A
- EPS
- PRFX N/A
- AEON 72.93
- Revenue
- PRFX N/A
- AEON N/A
- Revenue This Year
- PRFX N/A
- AEON N/A
- Revenue Next Year
- PRFX N/A
- AEON N/A
- P/E Ratio
- PRFX N/A
- AEON $0.01
- Revenue Growth
- PRFX N/A
- AEON N/A
- 52 Week Low
- PRFX $0.43
- AEON $0.38
- 52 Week High
- PRFX $16.63
- AEON $402.48
- Technical
- Relative Strength Index (RSI)
- PRFX 51.08
- AEON 26.87
- Support Level
- PRFX $1.92
- AEON $0.38
- Resistance Level
- PRFX $2.37
- AEON $0.43
- Average True Range (ATR)
- PRFX 0.27
- AEON 0.04
- MACD
- PRFX 0.07
- AEON 0.20
- Stochastic Oscillator
- PRFX 35.36
- AEON 56.29
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.